Inflarx Nv logo

Inflarx Nv Share Price (NASDAQ: IFRX)

$0.9

Last updated on

Check the interactive Inflarx Nv Stock chart to analyse performance

Inflarx Nv stock performance

as on August 23, 2025 at 1:29 AM IST

  • Today's Low:$0.85
    Today's High:$0.94

    Day's Volatility :9.27%

  • 52 Weeks Low:$0.71
    52 Weeks High:$2.82

    52 Weeks Volatility :74.73%

Inflarx Nv Stock Returns

PeriodInflarx NvIndex (Russel 2000)
3 Months
-50.12%
0.0%
6 Months
-43.26%
0.0%
1 Year
-42.54%
0.0%
3 Years
-61.04%
-7.8%

Inflarx Nv Key Stats

Check Inflarx Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.9
Open
$0.909
Today's High
$0.9388
Today's Low
$0.8518
Market Capitalization
$61.9M
Today's Volume
$601.4K
52 Week High
$2.815
52 Week Low
$0.7113
Revenue TTM
$162.8K
EBITDA
$-51.0M
Earnings Per Share (EPS)
$-0.85
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-65.07%

Stock Returns calculator for Inflarx Nv Stock including INR - Dollar returns

The Inflarx Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Inflarx Nv investment value today

Current value as on today

₹61,278

Returns

₹38,722

(-38.72%)

Returns from Inflarx Nv Stock

₹43,038 (-43.04%)

Dollar Returns*

₹4,316 (+4.32%)

Indian investors sentiment towards Inflarx Nv Stock

3%

Period: Jul 23, 2025 to Aug 22, 2025. Change in 30 Days versus previous period

Search interest for Inflarx Nv Stock from India on INDmoney has increased by 3% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Inflarx Nv

  • Name

    Holdings %

  • Suvretta Capital Management, LLC

    9.57%

  • 683 Capital Management LLC

    3.87%

  • Eversept Partners, LLC

    2.42%

  • Morgan Stanley - Brokerage Accounts

    1.86%

  • SILVERARC CAPITAL MANAGEMENT, LLC

    1.71%

  • Woodline Partners LP

    1.11%

Analyst Recommendation on Inflarx Nv Stock

Rating
Trend

Buy

    81%Buy

    18%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Inflarx Nv(by analysts ranked 0 to 5 stars)

Inflarx Nv Share Price Target

What analysts predicted

Upside of 329.11%

Target:

$3.86

Current:

$0.90

Inflarx Nv share price target is $3.86, a slight Upside of 329.11% compared to current price of $0.90 as per analysts' prediction.

Inflarx Nv Stock Insights

  • Price Movement

    In the last 3 months, IFRX stock has moved down by -50.9%
  • IFRX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.6% return, outperforming this stock by 109.1%
  • IFRX vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 109.5% return, outperforming this stock by 170.0%
  • Price to Sales

    ForIFRX every $1 of sales, investors are willing to pay $302.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Inflarx Nv Technicals Summary

Sell

Neutral

Buy

Inflarx Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Inflarx Nv Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Inflarx Nv logo
6.79%
-43.26%
-42.54%
-61.04%
-78.02%
Regeneron Pharmaceuticals, Inc. logo
4.38%
-17.37%
-50.85%
-2.23%
-0.91%
Beone Medicines Ltd logo
5.81%
21.35%
61.84%
78.01%
32.14%
Vertex Pharmaceuticals Incorporated logo
-16.34%
-17.97%
-17.9%
35.76%
47.74%
Alnylam Pharmaceuticals, Inc. logo
38.5%
82.49%
66.63%
105.56%
244.81%

About Inflarx Nv

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Organization
Inflarx Nv
Employees
74
CEO
Prof. Renfeng Guo M.D.
Industry
Health Technology

Key Management of Inflarx Nv

NameTitle
Prof. Renfeng Guo M.D.
Co-Founder, Chief Scientific Officer & Executive Director
Dr. Thomas Taapken Ph.D.
Chief Financial Officer
Ms. Derval O'Carroll
Senior VP and Global Head of Regulatory Affairs & Compliance
Dr. Camilla Chong M.D.
Chief Medical Officer
Mr. Jan Medina CFA
Head of Investor Relations & VP
Mr. Christian Schmid
VP and Head of Legal Affairs & General Counsel
Ms. Nicole Bertsch
Senior Director & Head of Human Resources
Dr. Maria Habel PH.D.
VP, Head of Preclinical R&D and QC
Dr. Bruce P. Burnett Ph.D.
VP & Head of Medical Affairs
Mr. Kofi Boaten
Senior Director and Head of Supply Quality & Clinical Trial Supplies

Important FAQs about investing in IFRX Stock from India :

What is Inflarx Nv share price today?

Inflarx Nv share price today is $0.90 as on at the close of the market. Inflarx Nv share today touched a day high of $0.94 and a low of $0.85.

What is the 52 week high and 52 week low for Inflarx Nv share?

Inflarx Nv share touched a 52 week high of $2.82 and a 52 week low of $0.71. Inflarx Nv stock price today i.e. is closed at $0.90, lower by 68.03% versus the 52 week high.

How to invest in Inflarx Nv Stock (IFRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Inflarx Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Inflarx Nv Shares that will get you 1.6667 shares as per Inflarx Nv share price of $0.90 per share as on August 23, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Inflarx Nv Stock (IFRX) from India?

Indian investors can start investing in Inflarx Nv (IFRX) shares with as little as ₹87.521 or $1 (as of August 23, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹875.21 in Inflarx Nv stock (as per the Rupee-Dollar exchange rate as on August 23, 2025). Based on Inflarx Nv share’s latest price of $0.90 as on August 23, 2025 at 1:29 AM IST, you will get 11.1111 shares of Inflarx Nv. Learn more about fractional shares .

What are the returns that Inflarx Nv has given to Indian investors in the last 5 years?

Inflarx Nv stock has given -78.02% share price returns and 18.0% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?